Trial Profile

A Proof-of-Concept Study of VK2809 for the Treatment of Glycogen Storage Disease Type Ia (GSD Ia)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 28 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VK 2809 (Primary)
Indications Glycogen storage disease type I
Focus Adverse reactions; Proof of concept
Sponsors Viking Therapeutics

Most Recent Events

09 Aug 2018 According to a Viking Therapeutics media release, the company plans to begin dosing patients in this trial in the third quarter of 2018.
17 Feb 2017 New trial record
14 Feb 2017 According to a Viking Therapeutics media release, the company plans to file an Investigational New Drug (IND) application for VK2809 for the treatment of GSD Ia and initiate this study in the second half of 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com